The stock of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) decreased by $0.0 on Tuesday to finish at $0.08, up 2.03 percent. The last five days have seen an average of 1,663,640 shares of common stock traded. 7 times new highs were reached in the current year, with a fall of -$0.4744. The average number of shares traded over the last 20 days was 8,312,340, while the average volume over the last 50 days totaled 3,973,858.
INFI stock dropped -36.59% since last month. On 08/28/23, the company’s shares reached a one-month low of $0.0790. The stock touched a high of $1.64 on 01/18/23, after rallying from a low of $0.08 in 52 weeks. The price of INFI stock has declined by -85.48% or -$0.4744 this year, reaching a new high 7 times. Still, the stock price is down -95.09% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
For the three months ended March 30, Infinity Pharmaceuticals Inc.’s quick ratio was 1.70, while its current ratio was 1.70, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 39.70% percent. Based on annual data, it had gross profit of $47.44 million and revenue of $2.59 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. INFI’s return on assets (ROA) during the last 12 months has been -113.00%. In the meantime, the return on equity (ROE) for the last 12 months was 171.20%.
Earnings Surprise
According to Infinity Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended March 30. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $0.58 million, while revenues fell by -18.97% to $0.73 million. It was predicted that Infinity Pharmaceuticals Inc.’s quarterly earnings would be -$0.12, but it ended up being -$0.1. EBITDA was -$10.01 million for the quarter. At the end of Infinity Pharmaceuticals Inc.’s most recent quarter ended March 30, its liabilities totaled 58.64 million, while its total debt was $0.63 million. Equity owned by shareholders amounts to $90.76 million.
Technical Picture
Here’s a quick look at Infinity Pharmaceuticals Inc.’s (INFI) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 33.57%, suggesting the stock is Neutral, with a 79.82% historical volatility rate.
The stochastic %K and %D were 5.89% and 6.17% respectively, while the average true range (ATR) was 0.0154. Based on the 14-day stochastic reading of 3.68%, the RSI (14) reading is 35.63%. On the 9-day MACD Oscillator, the stock is at -0.0072, and the 14-day reading is at -0.0113.
Analyst Ratings
In its analyst report released on October 18, 2021, H.C. Wainwright began covering Infinity Pharmaceuticals Inc. (NASDAQ: INFI). The stock was rated as a Buy by the brokerage firm. Analysts have assigned Infinity Pharmaceuticals Inc. (INFI) an Hold rating. INFI is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 0 others recommend it as a buy.
What is INFI’s price target for the next 12 months?
The current consensus forecast for the stock is between $0.30 and $0.30, with a median target price of $0.30. In analyzing these forecasts, the average price target given by analysts for Infinity Pharmaceuticals Inc. (INFI) is $0.30.
